Dr. Gitta Neufang takes over as head of Beiersdorf R&D
Dr. May Shana’a (60), Corporate Senior Vice President and Member of the Beiersdorf Executive Committee, has decided to retire this year. Effective March 1, 2021, she will, therefore, hand over her responsibilities to Dr. Gitta Neufang (47), currently Chief Innovation & Medical Officer for Beiersdorf’s Pharmacy Brands.
Expert in the field of dermatology and natural science
Gitta Neufang began her career at Beiersdorf AG in 2003 as a researcher for sensitive skin. In 2006, she took over as Head of the Laboratory for Dermatological Skin Care Research, focusing on skin diseases and problem skin. Before assuming her current role as Chief Innovation & Medical Officer, she led the “Eucerin” Actives & Clinicals team, which focused on dermocosmetic research into active ingredients and on conducting clinical studies. In 2014, she joined the Derma department and became the Global Director of Medical Management, and in 2019 she took over as Chief Medical & Innovation Officer Pharmacy Brands. Here, among other things, she steered the successful realignment of the innovation process for Derma and Health Care and aligned the innovation management. She was responsible for the medical deployment of “Eucerin” Anti-Pigment and has driven the dermatological skin care expertise of the “Eucerin” business in recent years.
“With Gitta Neufang, we have an externally highly recognized and internationally connected expert in the field of dermatology and natural sciences who combines many years of experience in research and business expertise,” said Stefan De Loecker, Chief Executive Officer of Beiersdorf AG. “I am pleased that with her we have an internal candidate who will further develop the area of skin research and innovation, which is at the core of Beiersdorf.”
Seven years of passion and service
Since 2014, May Shana’a has been leading the Beiersdorf R&D organization, driving successful key innovations and significantly expanding regional capabilities and reach. “Under her leadership, extensive progress has been achieved in areas like alternative testing, epigenetics, and the human microbiome,” said Stefan De Loecker. May Shana’a has been instrumental in bringing one of Beiersdorf’s biggest innovative ingredient successes ever to life – Thiamidol. The highly effective active disrupted the anti-pigment market and secured significant gains for the EUCERIN Derma business. During the same period, R&D teams under her leadership have been one of the key pillars of Beiersdorf’s sustainability agenda, achieving breakthroughs in sustainable product formulas and packaging, notably the exit from microplastics in formulas and the ongoing plastics reduction pledge. Stefan De Loecker: “We thank May Shana’a for her seven years of passionate and dedicated services to Beiersdorf. We wish her all the very best in the new phase of her life, after completing a highly commendable international career.”
“To end my executive management career by serving “Nivea” and “Eucerin” for the last seven years has been a special privilege. I am proud of my global R&D Team and the successes we have created together. I thank all my fellow Beiersdorf colleagues and stakeholders for supporting me since the very beginning. I wish my successor Gitta Neufang with the R&D community great success in creating the next episode of innovation at Beiersdorf,” says May Shana’a.